NEW YORK - A boyish-looking entrepreneur who became the new face of corporate greed when he jacked up the price of a lifesaving drug fiftyfold was led away in handcuffs by the FBI on unrelated fraud charges Thursday in a scene that left more than a few Americans positively gleeful.
Martin Shkreli, 32, a former hedge-fund manager and relentless self-promoter who has called himself "the world's most eligible bachelor" on Twitter, was arrested in a drab gray hoodie and taken into federal court in Brooklyn, where he pleaded not guilty. He was released on $5 million bail.
If convicted, Shkreli could get up to 20 years in prison. He left court without saying anything to reporters. His attorneys had no immediate comment.
Online, many people took delight in his arrest, calling him a greedy, arrogant "punk" who gave capitalism a bad name and got what was coming to him. Some cracked jokes about lawyers jacking up their hourly fees 5,000 percent to defend him in his hour of need.
Prosecutors said that between 2009 and 2014, Shkreli lost some of his hedge-fund investors' money through bad trades, then looted Retrophin, a pharmaceutical company where he was CEO, for $11 million to pay back his disgruntled clients.
Shkreli "engaged in multiple schemes to ensnare investors through a web of lies and deceit," U.S. Attorney Robert Capers said in a statement.
Shkreli was charged with securities fraud and conspiracy. A second defendant, lawyer Evan Greebel, of Scarsdale, N.Y., was charged with conspiracy and also pleaded not guilty.
In September, Shkreli was widely vilified after a drug company he founded, Turing Pharmaceuticals, spent $55 million for U.S. rights to sell a medicine called Daraprim and promptly raised the price from $13.50 to $750 per pill.
The 62-year-old drug is the only approved treatment for toxoplasmosis, a rare parasitic disease that mainly strikes pregnant women, cancer patients, and AIDS patients.
The move sparked outrage on the presidential campaign trail and helped prompt a Capitol Hill hearing on drug prices. Headlines called the Brooklyn-born Shkreli such thing as "America's most hated man," the "drug industry's villain," and "biotech's bad boy" - and those were just some of the more printable names.
Hillary Clinton called it price-gouging and said the company's behavior was "outrageous." Donald Trump called Shkreli "a spoiled brat." Bernie Sanders returned a donation from Shkreli.
Prosecutors said the investigation that led to Shkreli's arrest dated back to last year, before the furor over the drug-price increase.
Shkreli defended the increase by saying that insurance and other programs would enable patients to get the drug and that the profits would help fund research into new treatments.
But he also made an unapologetic business-is-business argument for the price jump. In fact, he recently said he probably should have raised it more.
"No one wants to say it, no one's proud of it, but this is a capitalist society, a capitalist system, and capitalist rules," he said in an interview at the Forbes Healthcare Summit this month. "And my investors expect me to maximize profits, not to minimize them or go half or go 70 percent, but to go to 100 percent of the profit curve."
Amid the uproar, Shkreli said Turing would cut the price of Daraprim. Last month, however, Turing reneged. Instead, the company is reducing what it charges hospitals for Daraprim by as much as 50 percent.
While most patients' co-payments will be $10 or less a month, insurance companies will be stuck with the bulk of the tab, potentially driving up future treatment and insurance costs.
Shkreli is known as a prolific user of Twitter and often livestreams his workday over the Internet, inviting people to chat with him at his desk. He refers to those who follow him online as his "fans."
Recently it emerged that he bought the only copy of a Wu-Tang Clan album titled Once Upon a Time in Shaolin, which the hip-hop group sold on the condition that it not be released publicly. He said he paid $2 million.
Capers, the chief federal prosecutor, sidestepped a question about whether authorities had seized Shkreli's album, and said: "We're not aware of how he raised the funds to buy the Wu-Tang album."
Last month, Shkreli was named chairman and CEO of KaloBios Pharmaceuticals after buying a majority stake in the struggling cancer-drug developer.